Journal
CELL METABOLISM
Volume 20, Issue 5, Pages 753-760Publisher
CELL PRESS
DOI: 10.1016/j.cmet.2014.07.006
Keywords
-
Categories
Funding
- Swedish Research Council
- Swedish Diabetes Foundation
- Swedish Heart Lung Foundation
- Swedish Foundation for Strategic Research
- Knut and Alice Wallenberg foundation
- Goran Gustafsson Foundation
- Ingbritt and Arne Lundberg's foundation
- TorstenSoderberg's Foundation
- Ragnar Soderberg's Foundation
- NovoNordisk Foundation
- AFA insurances
- LUA-ALF from Vastra Gotalands regionen
- Stockholm County Council
- ERC (European Research Council) [615362 - METABASE]
- FP7-EU consortium grant (RESOLVE)
- FP7-EU consortium grant (MyNewGut)
- CVON grant (IN-CONTROL)
- Novo Nordisk Fonden [NNF13OC0008163] Funding Source: researchfish
Ask authors/readers for more resources
The gut microbiota has emerged as an integral factor that impacts host metabolism and has been suggested to play a vital role in metabolic diseases such as obesity, insulin resistance, type 2 diabetes, and cardiovascular disease. In humans, cross-sectional studies have identified microbiota profiles associated with metabolic diseases, whereas causation mainly has been demonstrated in animal models. Recent studies involving microbiota-based interventions in humans, or transfer of disease-associated microbiota into germ-free mice, underscore that an altered microbiota may directly modulate host metabolism in humans. However, it will be essential to determine whether an altered gut microbiota precedes development of insulin resistance and diabetes and to identify the underlying molecular mechanisms. Increased mechanistic insights of how the microbiota modulates metabolic disease in humans may pave the way for identification of innovative microbiota-based diagnostics and/or therapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available